What is HC Wainwright’s Estimate for CNTX Q3 Earnings?

Context Therapeutics Inc. (NASDAQ:CNTX) – Analysts at HC Wainwright issued their Q3 2025 EPS estimates for shares of Context Therapeutics in a research note issued to investors on Friday, March 21st. HC Wainwright analyst E. Bodnar expects that the company will post earnings of ($0.05) per share for the quarter. HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Context Therapeutics’ current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Context Therapeutics’ Q4 2025 earnings at ($0.05) EPS.

Context Therapeutics (NASDAQ:CNTX) last announced its earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.01.

Several other research firms have also recently commented on CNTX. Citizens Jmp upgraded shares of Context Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 8th. D. Boral Capital restated a “buy” rating and set a $9.00 price objective on shares of Context Therapeutics in a report on Friday, March 21st. Finally, JMP Securities started coverage on shares of Context Therapeutics in a research note on Wednesday, January 8th. They issued an “outperform” rating and a $4.00 target price for the company. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $6.17.

Context Therapeutics Stock Up 13.2 %

Shares of CNTX stock opened at $0.87 on Monday. Context Therapeutics has a 12 month low of $0.64 and a 12 month high of $2.75. The firm has a market cap of $64.87 million, a PE ratio of -0.95 and a beta of 2.06. The stock has a 50 day moving average of $0.84 and a 200-day moving average of $1.41.

Hedge Funds Weigh In On Context Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Jane Street Group LLC bought a new stake in Context Therapeutics in the fourth quarter valued at about $29,000. Citadel Advisors LLC acquired a new stake in Context Therapeutics during the fourth quarter valued at approximately $31,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Context Therapeutics in the 3rd quarter valued at approximately $89,000. Shay Capital LLC acquired a new position in shares of Context Therapeutics in the 4th quarter worth approximately $52,000. Finally, Clear Harbor Asset Management LLC lifted its position in shares of Context Therapeutics by 60.6% during the 4th quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company’s stock worth $61,000 after buying an additional 21,804 shares during the period. Institutional investors and hedge funds own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.